A safety estimand for late phase clinical trials where the analysis period varies over the subjects.

It is valuable, and possible, to use the International Council for Harmonisation estimand framework not only for efficacy but also for safety evaluation, with the estimand driven by an interpretable, and relevant, clinical question.